A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors

Xiangchuan Wen,1 Baojie Wang,1 Chunjuan Wang,1,2 Chenglin Han,3 Shougang Guo1,2 1Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, People’s Republic of China; 2Department of Neurology, Shandong Provincial Hospit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wen X, Wang B, Wang C, Han C, Guo S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	gababr encephalitis immunotherapy tumour treatment cd19+ cell percentage prognosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/4f1d52090cee4685a5ae82366afffbd4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f1d52090cee4685a5ae82366afffbd4
record_format	dspace
spelling	oai:doaj.org-article:4f1d52090cee4685a5ae82366afffbd42021-12-02T10:57:12ZA Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors1178-2021https://doaj.org/article/4f1d52090cee4685a5ae82366afffbd42021-01-01T00:00:00Zhttps://www.dovepress.com/a-retrospective-study-of-patients-with-gababr-encephalitis-therapy-dis-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Xiangchuan Wen,1 Baojie Wang,1 Chunjuan Wang,1,2 Chenglin Han,3 Shougang Guo1,2 1Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, People’s Republic of China; 2Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, People’s Republic of China; 3Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, People’s Republic of ChinaCorrespondence: Shougang GuoDepartment of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jing Wu Road, Huaiyin District, Jinan, 250021 Shandong, People’s Republic of ChinaTel +86-13220585081Email guoshougang1124@163.comPurpose: To explore the effects of immunotherapy and tumour treatment on patients with GABABR encephalitis, evaluate the correlation between immune cell subsets and disease activity, and investigate effective prognostic factors.Patients and Methods: Twenty patients with γ-aminobutyric acid B receptor (GABABR) encephalitis were enrolled from December 2015 to April 2020. The clinical data, modified Rankin Scale (mRS) score, prognosis and percentage of serum lymphocytes were recorded.Results: All patients received first-line immunotherapy. The median mRS scores were 4 and 3 before and after first-line immunotherapy (P< 0.01). Seven patients received second-line immunotherapy and had median mRS scores of 3 and 2 before and after second-line immunotherapy (P=0.015). Small-cell lung cancer was detected in twelve patients. Among the patients who died because of tumours, patients who received tumour treatment lived longer than patients who did not receive tumour treatment (P=0.025). All four surviving patients who received tumour treatment had good outcomes (mRS≤ 2). The median serum CD19+B cell percentage in sixteen patients were 20.00% and 13.42% prior first-line immunotherapy and at the last follow-up (P< 0.01). After a maximum follow-up of 54 months (median: 12; range: 3– 54), eleven patients (55%) had a poor prognosis (mRS> 2). Predictors of a poor prognosis were older age (P=0.031), delayed initial improvement after immunotherapy (> 4 weeks) (P=0.038) and respiratory failure (P=0.038).Conclusion: Aggressive immunotherapy and tumour treatment contribute to improvements in neurological function and a better prognosis of patients with GABABR encephalitis. The serum CD19+B cell percentage may be an indicator of disease activity. Older age, delayed initial improvement after immunotherapy, and respiratory failure may be associated with poor outcomes.Keywords: GABABR encephalitis, immunotherapy, tumour treatment, CD19+B cell percentage, prognosisWen XWang BWang CHan CGuo SDove Medical Pressarticlegababr encephalitisimmunotherapytumour treatmentcd19+ cell percentageprognosisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 99-110 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	gababr encephalitis immunotherapy tumour treatment cd19+ cell percentage prognosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	gababr encephalitis immunotherapy tumour treatment cd19+ cell percentage prognosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Wen X Wang B Wang C Han C Guo S A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors
description	Xiangchuan Wen,1 Baojie Wang,1 Chunjuan Wang,1,2 Chenglin Han,3 Shougang Guo1,2 1Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, People’s Republic of China; 2Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, People’s Republic of China; 3Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, People’s Republic of ChinaCorrespondence: Shougang GuoDepartment of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jing Wu Road, Huaiyin District, Jinan, 250021 Shandong, People’s Republic of ChinaTel +86-13220585081Email guoshougang1124@163.comPurpose: To explore the effects of immunotherapy and tumour treatment on patients with GABABR encephalitis, evaluate the correlation between immune cell subsets and disease activity, and investigate effective prognostic factors.Patients and Methods: Twenty patients with γ-aminobutyric acid B receptor (GABABR) encephalitis were enrolled from December 2015 to April 2020. The clinical data, modified Rankin Scale (mRS) score, prognosis and percentage of serum lymphocytes were recorded.Results: All patients received first-line immunotherapy. The median mRS scores were 4 and 3 before and after first-line immunotherapy (P< 0.01). Seven patients received second-line immunotherapy and had median mRS scores of 3 and 2 before and after second-line immunotherapy (P=0.015). Small-cell lung cancer was detected in twelve patients. Among the patients who died because of tumours, patients who received tumour treatment lived longer than patients who did not receive tumour treatment (P=0.025). All four surviving patients who received tumour treatment had good outcomes (mRS≤ 2). The median serum CD19+B cell percentage in sixteen patients were 20.00% and 13.42% prior first-line immunotherapy and at the last follow-up (P< 0.01). After a maximum follow-up of 54 months (median: 12; range: 3– 54), eleven patients (55%) had a poor prognosis (mRS> 2). Predictors of a poor prognosis were older age (P=0.031), delayed initial improvement after immunotherapy (> 4 weeks) (P=0.038) and respiratory failure (P=0.038).Conclusion: Aggressive immunotherapy and tumour treatment contribute to improvements in neurological function and a better prognosis of patients with GABABR encephalitis. The serum CD19+B cell percentage may be an indicator of disease activity. Older age, delayed initial improvement after immunotherapy, and respiratory failure may be associated with poor outcomes.Keywords: GABABR encephalitis, immunotherapy, tumour treatment, CD19+B cell percentage, prognosis
format	article
author	Wen X Wang B Wang C Han C Guo S
author_facet	Wen X Wang B Wang C Han C Guo S
author_sort	Wen X
title	A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors
title_short	A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors
title_full	A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors
title_fullStr	A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors
title_full_unstemmed	A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors
title_sort	retrospective study of patients with gababr encephalitis: therapy, disease activity and prognostic factors
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/4f1d52090cee4685a5ae82366afffbd4
work_keys_str_mv	AT wenx aretrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors AT wangb aretrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors AT wangc aretrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors AT hanc aretrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors AT guos aretrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors AT wenx retrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors AT wangb retrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors AT wangc retrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors AT hanc retrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors AT guos retrospectivestudyofpatientswithgababrencephalitistherapydiseaseactivityandprognosticfactors
_version_	1718396400199270400

A Retrospective Study of Patients with GABABR Encephalitis: Therapy, Disease Activity and Prognostic Factors

Ejemplares similares